I am...
All
- All
- HLH/FEL/FHL
- LCH
- Rare Histiocytic Disorders and Other Topics
- RDD
Janus Kinase Inhibition as a Novel Treatment for Hemophagocytic Lymphohistiocytosis
Principal Investigator Kim E. Nichols, MD University of Pennsylvania Perelman School of Medicine The Children’s Hospital of…
Gene Therapy in a Mouse Model of Virus-triggered X-linked Lymphoproliferative Disease (XLP1): Control of Infection and Disease Progression
Principal Investigator Peter Aichele, PhD University Medical Center Freiburg, University of Freiburg – Freiburg, Germany Date of…
Unraveling the Pathophysiological Role of the BRAFV600E Mutation in Langerhans Cell Histiocytosis (LCH) and its Therapeutical Implications with Murine Models of High-Risk LCH
Principal Investigator Miriam Merad, MD, PhD Icahn School of Medicine at Mount Sinai – New York, New…
Histiocyte Society Clinical Trials Database System LCH-IV Treatment Protocol Study
Project Administrators Histiocyte Society Executive Board LCH Study Reference Center – Vienna, Austria Date of Award December…
Dysregulation of Dendritic Cell Development in Langerhans Cell Histiocytosis
Principal Investigator Matthew Collin, MD Newcastle University – Newcastle upon Tyne, United Kingdom Date of Award December…